Andrew Hill Investment Advisors Inc. Makes New Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Andrew Hill Investment Advisors Inc. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,608 shares of the company’s stock, valued at approximately $2,003,000. IDEXX Laboratories accounts for about 2.1% of Andrew Hill Investment Advisors Inc.’s holdings, making the stock its 26th biggest position.

Other institutional investors also recently bought and sold shares of the company. OFI Invest Asset Management bought a new position in shares of IDEXX Laboratories during the third quarter worth about $25,000. Valley National Advisers Inc. lifted its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $26,000. Geo Capital Gestora de Recursos Ltd acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at about $28,000. Finally, Covestor Ltd lifted its holdings in IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after acquiring an additional 28 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP George Fennell sold 8,198 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,524 shares of company stock worth $24,871,960. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Down 0.6 %

Shares of NASDAQ IDXX traded down $2.75 during mid-day trading on Friday, reaching $475.04. The company had a trading volume of 151,699 shares, compared to its average volume of 423,657. The stock has a fifty day moving average of $539.94 and a two-hundred day moving average of $508.49. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The company has a market capitalization of $39.45 billion, a price-to-earnings ratio of 47.45, a PEG ratio of 3.68 and a beta of 1.26. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. During the same quarter in the prior year, the company posted $2.05 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of research analyst reports. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. The Goldman Sachs Group upped their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research note on Tuesday, January 30th. Finally, Barclays upped their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.